News
Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous ...
Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...
Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug ...
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...
Explore more
1d
Zacks Investment Research on MSNRegeneron Initial Data on Multiple Myeloma Drug EncouragingRegeneron Pharmaceuticals, Inc. REGN announced encouraging initial results from two cohorts of the early-stage study on ...
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...
Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...
Pittsburgh, Pennsylvania Saturday, May 24, 2025, 15:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results